Qin et al. demonstrated that Src activation can induce resistance to the EGFR inhibitor, gefitinib, by activating the Akt- and/or Erk-signaling pathways in gallbladder adenocarcinoma cells [38]. This evidence concerns the gene AKT1 and gallbladder adenocarcinoma.